Abstract: Various embodiments of the present technology generally relate to systems and methods for providing an analytics service governance system to provide data visualizations of system-level metadata. In certain embodiments, a method may comprise operating a data analytics system to implement an analytics service governance process to generate data visualizations (DVs) of system-level metadata using an analytics service configured to generate DVs of user-provided datasets.

Abstract: The embodiments described herein relate to chemically and mechanically durable glass compositions and glass articles formed from the same. In embodiments, the glass composition may include 74-78 mol. % SiO2; X mol. % Al2O3, wherein X is 5-7; alkaline earth oxide comprising MgO and CaO, wherein: CaO is 0.1-1.0 mol. %; MgO is 4-7 mol. %; and a ratio (CaO (mol. %)/(CaO (mol. %)+MgO (mol. %)) is less than or equal to 0.5. The glass composition may further include Y mol. % alkali oxide, wherein the alkali oxide comprises 9-13 mol. % Na2O and less than or equal to 0.4 mol. % of a fining agent. The glass composition may be free of boron and compounds of boron.

Abstract: A device for restoration by encapsulation of a breached, leaking, or degraded pressure retention item. The apparatus may include multiple features for reducing loads on the pressure retention item, including a filler or liner plate, filler material, and an angled attachment point between the apparatus and the pressure retention item. The apparatus may include inspection ports for viewing, pressure, or leak detection. The apparatus may include a guide track for improved welding to fasten the apparatus to the pressure retaining item. The apparatus may include an expansion joint or bellows, allowing lateral and/or axial movement of the device and/or the pressure retaining item.

Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.

Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.

Abstract: The present invention relates to compounds of formula (I) that have the ability to be used as metal complexes in radiotherapy. wherein A is selected from the group consisting of CO2R1, and PO3R1; B is selected from the group consisting of CO2R2, and PO3R2; R1, R2 and R3 are each independently selected from the group consisting of H and C1-C12alkyl; each Ra is independently selected from the group consisting of H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OH, OCH3, OCH2CH3, CF3, OCF3, NO2, NH2, and CN; each Rb is independently selected from the group consisting of H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OH, OCH3, OCH2CH3, CF3, OCF3, NO2, NH2, and CN; L is a linker having from 1 to 20 atoms in the normal chain; or a pharmaceutically acceptable salt thereof.

Abstract: Direct conflict mitigation in near real-time radio access network intelligent controllers is provided. A method for direct conflict mitigation in near real-time radio access network intelligent controllers may include determining a potential conflict between subsets of services that are requested for two or more applications among an available set of services of an intelligent controller. The apparatus may transmit conflict negotiation requests to each of the two or more applications requesting that the two or more applications perform conflict negotiation between each other to allocate the subsets of services among the available set of services, and process responses from each of the two or more applications indicating results of the conflict negotiation.

Abstract: The present invention relates to compounds that can complex a radionuclide and formulations and kits comprising compounds that can complex a radionuclide. The compounds, formulations and kits are of use in radiotherapy and diagnostic imaging.

Abstract: A device for wound irrigation and debridement includes a body extending along a longitudinal axis. The body comprises an interior region and an opening such that that the interior region and the first opening are configured to transfer an irrigation fluid. The body comprises a compliant region having a first stiffness and a debridement region having a different second stiffness. The compliant region defines a distal surface. In a first configuration, the compliant region defines a first axial dimension, the distal surface engages a target body region, and the debridement region is axially offset from the distal surface and disengaged from the target body region. In a second configuration, the compliant region is compressed to define a second axial dimension less than the first axial dimension, thereby engaging the debridement region with the target body region, and the distal surface engages the target body region.

Abstract: Among other things, we describe techniques for automatic annotation of environmental features in a map during navigation of a vehicle. The techniques include receiving, by the vehicle located within an environment, a map of the environment. Sensors of the vehicle receive sensor data and semantic data. The sensor data includes a plurality of features of the environment. A geometric model of a feature of the plurality of features is generated. The feature is associated with a drivable area within the environment. A drivable segment is extracted from the drivable area. The drivable segment is segregated into a plurality of geometric blocks, wherein each geometric block corresponds to a characteristic of the drivable area and the geometric model of the feature includes the plurality of geometric blocks. The geometric model is annotated using the semantic data. The annotated geometric model is embedded within the map.

Abstract: A device for wound irrigation and debridement includes a body extending along a longitudinal axis. The body comprises an interior region and an opening such that that the interior region and the first opening are configured to transfer an irrigation fluid. The body comprises a compliant region having a first stiffness and a debridement region having a different second stiffness. The compliant region defines a distal surface. In a first configuration, the compliant region defines a first axial dimension, the distal surface engages a target body region, and the debridement region is axially offset from the distal surface and disengaged from the target body region. In a second configuration, the compliant region is compressed to define a second axial dimension less than the first axial dimension, thereby engaging the debridement region with the target body region, and the distal surface engages the target body region.

Abstract: The present invention is directed to sarcophagine based compounds of formula (I). The compounds can complex a radioisotope, such as 64-copper and hence are useful in radioimaging and radiotherapy of cancers, e.g. colorectal cancer. The compounds work via a pre-targeting imaging approach in which the tetrazine reacts via click chemistry with a functional group such as a transcyclooctene which is pre-bound to a ligand such as a tumour specific antibody.

Abstract: A personal cleansing composition comprising: i) a piroctone compound: ii) a cleansing surfactant comprising amphoteric surfactant and an ethoxylated alkyl sulphate surfactant in which the weight ratio of ethoxylated alkyl sulphate to amphoteric surfactant is from 2:1 to 6:1 iii) a cationic polymer in which the cationic polymer comprises poly quaternium 6.

Abstract: A sulphate-free-surfactant cleansing composition comprising, in an aqueous continuous phase: a total amount of anionic surfactant and amphoteric surfactant consisting of: (i) from 3 wt % to 13 wt %, by weight of the total composition at 100% activity, of an alpha olefin sulfonate anionic surfactant of general formula (I): R1—CH?CH—CH2—SO3-M+ (I) in which R1 is selected from linear or branched alkyl groups having from 11 to 13 carbon atoms and mixtures thereof; and M is a solubilizing cation; (ii) from 1 to 8 wt %, by weight of amphoteric surfactant, which is cocamidopropyl betaine; (iii) from 0.05 wt % to 0.5 wt % of a cationic polymer; (iv) from 0.3 to 2.8 wt % an inorganic electrolyte; and (v) water; in which the weight ratio of (i) to (ii) ranges from 2:1 to 1:4 and the pH of the composition is from 3 to 6.

Abstract: A glass container for storing pharmaceutical formulations may include a glass body formed from a Type IA or Type IB glass composition according to ASTM Standard E438-92(2011). The glass body may include a wall portion with an inner surface and an outer surface, a heel portion and a floor portion, wherein the inner surface of the glass container is formed by the inner surface of the glass body. The glass body may include at least a class A2 base resistance or better according to ISO 695, at least a type HGB2 hydrolytic resistance or better according to ISO 719 and Type 1 chemical durability according to USP <660>. The glass container does not comprise a boron-rich layer on the inner surface of the glass body in as formed condition.

Abstract: A coated glass package comprising a glass body having a Type 1 chemical durability according to USP 660, at least a class A2 base resistance or better according to ISO 695, and at least a type HGB2 hydrolytic resistance or better according to ISO 719. A lubricous coating having a thickness of ?100 microns may be positioned on at least a portion of the exterior surface of the glass body. The portion of the coated glass package with the lubricous coating comprises a coefficient of friction that is at least 20% less than an uncoated glass package and the coefficient of friction does not increase by more than 30% after undergoing a depyrogenation cycle. A horizontal compression strength of the coated glass package is at least 10% greater than an uncoated glass package and the horizontal compression strength is not reduced by more than 20% after undergoing the depyrogenation cycle.

Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.

Abstract: An electric heating mat may include an outer sleeve having an interior, and an access end with an opening to the interior. The access end may be folded upon itself into a closed condition, and unfolded into an opened condition. When the access end is closed, the interior of the outer sleeve may provide a sealed enclosure. The sealed enclosure may accommodate and protect internal components, such as heating elements, a power source, and associated controls. The heating elements, associated wiring, and an insulation layer may be provided in an inner sleeve, which may be insertable into the outer sleeve as a unit. When the access end is opened, the opening provides access to the internal components. Such access allows the power source to be turned on to supply power to the heating elements.

Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.

Abstract: A glass container for storing pharmaceutical formulations may include a glass body formed from a Type IA or Type IB glass composition according to ASTM Standard E438-92(2011). The glass body may include a wall portion with an inner surface and an outer surface, a heel portion and a floor portion, wherein the inner surface of the glass container is formed by the inner surface of the glass body. The glass body may include at least a class A2 base resistance or better according to ISO 695, at least a type HGB2 hydrolytic resistance or better according to ISO 719 and Type 1 chemical durability according to USP <660>. The glass container does not comprise a boron-rich layer on the inner surface of the glass body in as formed condition.